You are here

  • Home
  • Archive
  • Volume 11, Issue 7
  • IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation

 

Online download statistics by month:

Online download statistics by month: July 2023 to August 2025

AbstractFullPdf
Jul 2023425428248
Aug 2023466470127
Sep 202315015039
Oct 202314414545
Nov 202316216265
Dec 2023859162
Jan 2024979781
Feb 2024585829
Mar 2024959787
Apr 2024949456
May 2024909040
Jun 202410310354
Jul 2024888848
Aug 2024787873
Sep 2024797938
Oct 2024696938
Nov 2024788121
Dec 202423023324
Jan 2025919243
Feb 202517217211
Mar 2025959539
Apr 202510910931
May 2025787823
Jun 2025656520
Jul 2025110
Aug 2025220
Total320432271342